These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 1344660

  • 21. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen.
    Lowe NJ, Weingarten D, Bourget T, Moy LS.
    J Am Acad Dermatol; 1986 May; 14(5 Pt 1):754-60. PubMed ID: 3711379
    [Abstract] [Full Text] [Related]

  • 22. PUVA erythemal sensitivity depends on plasma psoralen concentration and UVA sensitivity.
    Sakuntabhai A, Farr PM, Diffey BL.
    Br J Dermatol; 1993 May; 128(5):561-5. PubMed ID: 8504050
    [Abstract] [Full Text] [Related]

  • 23. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
    Delrosso G, Bornacina C, Farinelli P, Bellinzona F, Leigheb G, Colombo E.
    Dermatology; 2008 May; 216(3):191-3. PubMed ID: 18182808
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis.
    Stephens RB, Cooper A.
    Australas J Dermatol; 1999 Nov; 40(4):217-9. PubMed ID: 10570561
    [Abstract] [Full Text] [Related]

  • 25. Bath-water delivery of 8-methoxypsoralen therapy for psoriasis.
    Collins P, Rogers S.
    Clin Exp Dermatol; 1991 May; 16(3):165-7. PubMed ID: 1934565
    [Abstract] [Full Text] [Related]

  • 26. Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis.
    Brücke J, Tanew A, Ortel B, Hönigsmann H.
    Br J Dermatol; 1991 Apr; 124(4):372-4. PubMed ID: 2025558
    [Abstract] [Full Text] [Related]

  • 27. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P, Makki S, Humbert P, Khaldoun H, Agache P.
    Acta Derm Venereol; 1992 Apr; 72(1):65-7. PubMed ID: 1350152
    [Abstract] [Full Text] [Related]

  • 28. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients.
    Herfst MJ, De Wolff FA.
    Clin Pharmacol Ther; 1983 Jul; 34(1):117-24. PubMed ID: 6861433
    [Abstract] [Full Text] [Related]

  • 29. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
    Nimkulrat P, Leenutaphong V, Sudtim S.
    J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
    [Abstract] [Full Text] [Related]

  • 30. Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA.
    Legat FJ, Hofer A, Quehenberger F, Kahofer P, Kerl H, Wolf P.
    J Am Acad Dermatol; 2004 Nov; 51(5):746-54. PubMed ID: 15523353
    [Abstract] [Full Text] [Related]

  • 31. Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man.
    Ljunggren B, Bjellerup M, Carter DM.
    J Invest Dermatol; 1981 Feb; 76(2):73-5. PubMed ID: 7462679
    [Abstract] [Full Text] [Related]

  • 32. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
    Man I, McKinlay J, Dawe RS, Ferguson J, Ibbotson SH.
    J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
    [Abstract] [Full Text] [Related]

  • 33. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
    Tanew A, Kipfelsperger T, Seeber A, Radakovic-Fijan S, Hönigsmann H.
    J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
    [Abstract] [Full Text] [Related]

  • 34. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.
    Calzavara-Pinton PG, Ortel B, Hönigsmann H, Zane C, De Panfilis G.
    Dermatology; 1994 Apr; 189(3):256-9. PubMed ID: 7949478
    [Abstract] [Full Text] [Related]

  • 35. Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (Meladinine) in local PUVA therapy.
    Shephard SE, Schregenberger N, Dummer R, Panizzon RG.
    Dermatology; 1998 Apr; 197(1):25-30. PubMed ID: 9693181
    [Abstract] [Full Text] [Related]

  • 36. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
    Asawanonda P, Amornpinyokeit N, Nimnuan C.
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):50-5. PubMed ID: 18181973
    [Abstract] [Full Text] [Related]

  • 37. Initial photochemotherapy of psoriasis with orally administered 8-methoxypsoralen and longwave ultraviolet light (PUVA).
    Siddiqui AH, Cormane RH.
    Br J Dermatol; 1979 Mar; 100(3):247-50. PubMed ID: 435382
    [Abstract] [Full Text] [Related]

  • 38. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.
    Grundmann-Kollmann M, Podda M, Bräutigam L, Hardt-Weinelt K, Ludwig RJ, Geisslinger G, Kaufmann R, Tegeder I.
    Br J Clin Pharmacol; 2002 Nov; 54(5):535-9. PubMed ID: 12445034
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B, Oguz O.
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [Abstract] [Full Text] [Related]

  • 40. Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization.
    Koulu LM, Jansén CT.
    J Am Acad Dermatol; 1988 May; 18(5 Pt 1):1053-9. PubMed ID: 2968374
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.